Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.

[1]  J. Ajani,et al.  Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer , 2022, Nature.

[2]  M. Moehler,et al.  Immunotherapy in Gastric Cancer , 2022, Current oncology.

[3]  J. Ajani,et al.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  H. Collins,et al.  Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer , 2021, mAbs.

[6]  E. Van Cutsem,et al.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. , 2020, The Lancet. Oncology.

[7]  Y. Bang,et al.  Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Leah M Chase,et al.  Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma , 2019, Clinical Cancer Research.

[9]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[10]  V. Miller,et al.  FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape , 2019, The oncologist.

[11]  Jun Yu,et al.  Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis , 2019, Cells.

[12]  J. Lacy,et al.  Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[13]  E. Baba,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Katoh.  Fibroblast growth factor receptors as treatment targets in clinical oncology , 2018, Nature Reviews Clinical Oncology.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  Sin-Ho Jung,et al.  FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival , 2016, Modern Pathology.

[17]  B. Sennino,et al.  Abstract 1407: FPA144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic tumor model , 2016 .

[18]  H. Lee,et al.  Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer , 2015, Pathobiology.

[19]  A. Ochiai,et al.  Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma , 2015, Gastric Cancer.

[20]  K. L. Pierce,et al.  Abstract 5446: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification , 2014 .

[21]  K. Baker,et al.  FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients. , 2014 .

[22]  H. Grabsch,et al.  FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study , 2014, British Journal of Cancer.

[23]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[24]  K. Matsumoto,et al.  FGFR2 gene amplification and clinicopathological features in gastric cancer , 2012, British Journal of Cancer.